Therapeutic Advances in Psychopharmacology
July 1, 2026
Martin Krsak, David Sparrow, Bernard Rosner et al.
Clinical trials with psychedelics face several challenges that are not present to such a degree with other pharmacotherapeutics. Psychedelic therapies often include a significant therapeutic container, including preparatory and integrative psychotherapy, along with supportive intervention during dosing sessions. All these are likely to have an effect on the outcomes. Additionally, the influence...
Psychotherapy and Psychosomatics
June 19, 2026
Judith Rohde, Tyler M Moore, Kathryn Walker et al.
Ketamine combined with psychotherapy has shown promise in treating posttraumatic stress disorder (PTSD), but predictors of clinical benefit remain unclear. In this systematic review and individual participant data meta-analysis (IPDMA), we examined patient- and treatment-level predictors of PTSD symptom change after combined treatment. Eligible studies combined ketamine with psychotherapy in...
Therapeutic Advances in Psychopharmacology
October 1, 2025
Luke Flynn, Martin Krsak, Mary Rondeau et al.
Background: Job-related stress and its extreme form, burnout, continue to affect almost half of all frontline healthcare workers and first responders. Current treatments are inadequate. Objectives: To evaluate a model of ketamine-assisted psychotherapy (KAP) delivered in a group format to address symptoms of anxiety, depression, trauma, and burnout via repeated measures of the Generalized...
Psychedelic Medicine
April 21, 2025
Luke Flynn, Mary Rondeau, Martin Krsak et al.
1 citation
Introduction: Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder. Ketamine-assisted psychotherapy (KAP) is part of an emerging model of psychedelic medicine that employs psychoactive agents to support the psychotherapeutic...